Author Archives: admin


Stem Cell Clinic > Articles by: admin

BioCryst to Present at Upcoming Virtual Investment Conferences

By Global News Feed

RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Evercore ISI 3rd Annual HealthCONx on Wednesday, December 2, 2020 at 12:35 p.m. ET and at the Piper Sandler 32nd Annual Healthcare Conference. Both conferences are being conducted as virtual events.

Read the original:
BioCryst to Present at Upcoming Virtual Investment Conferences

BioRestorative Therapies Emerges from Chapter 11 Reorganization

By Global News Feed

MELVILLE, N.Y., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today that its amended joint plan of reorganization has become effective and it has emerged from Chapter 11 reorganization. Pursuant to the confirmed plan of reorganization, the Company has received $3,848,000 in financing. The confirmed plan of reorganization also provides for additional funding, subject to certain conditions, of $3,500,000 less the sum of the debtor-in-possession financing provided to the Company during the reorganization (approximately $1,227,000) and the costs incurred by the debtor-in-possession lender.

Read more here:
BioRestorative Therapies Emerges from Chapter 11 Reorganization

New Test for Triaging Preeclampsia Passes Key Development Milestone: Progenity Releases Prospective Clinical Verification Data for its Preecludia™…

By Global News Feed

High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of preeclampsia High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of preeclampsia

Read more:
New Test for Triaging Preeclampsia Passes Key Development Milestone: Progenity Releases Prospective Clinical Verification Data for its Preecludia™...

Harrow Health Announces Participation at the Piper Sandler 32nd Annual Healthcare Conference

By Global News Feed

NASHVILLE, Tenn., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that Mark Baum, Harrow’s Chief Executive Officer, and Andrew Boll, Harrow’s Chief Financial Officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place December 1 – 3, 2020.

Go here to read the rest:
Harrow Health Announces Participation at the Piper Sandler 32nd Annual Healthcare Conference

Todos Medical Announces Positive In Vitro Data for Tollovid™ Confirming 3CL Protease Inhibition Mechanism of Action

By Global News Feed

NEW YORK, NY, REHOVAT, ISRAEL, SINGAPORE, Nov. 20, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire  -- Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced positive in vitro data by its joint venture partner NLC Pharma for the Company’s dietary supplement Tollovid™, demonstrating its ability to inhibit the 3CL protease. The 3CL protease is an enzyme that is required for the intracellular replication of coronaviruses. Tollovid received a certificate of free sale from the FDA in August 2020 and is being launched commercially into the US market initially at botanical wellness store The Alchemist’s Kitchen™ in New York City.

Visit link:
Todos Medical Announces Positive In Vitro Data for Tollovid™ Confirming 3CL Protease Inhibition Mechanism of Action

Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting

By Global News Feed

CAMBRIDGE, Mass. and NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) --  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the nomination of BDTX-1535 as the Company’s development candidate for the treatment of glioblastoma multiforme (GBM), as well as the commencement of Investigational New Drug (IND)-enabling studies.

See the original post here:
Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting

Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

By Global News Feed

MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.

See the original post:
Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

→←